Effect on substrate binding of an alteration at the conserved aspartic acid 162 in herpes simplex virus type 1 thymidine kinase

Despite the extensive use of antiviral drugs for the treatment of herpesvirus infections and as prodrugs for ablative gene therapy of cancer, little structural information about the drug activating enzyme, herpes simplex virus type 1 thymidine kinase (TK), was available until recently. In the absence of the three-dimensional structure we sought to elucidate the function of the key aspartic acid residue (D162) present within a highly conserved tri-peptide motif that is thought to function in nucleoside binding. In this study we generated a mutant, D162Q, by site-directed mutagenesis, purified both the wild-type and mutant TKs to near homogeneity by single-step affinity chromatography and determined the kinetic parameters for thymidine, ATP, dTMP and dTTP interactions, A 12-fold increase in K-m for thymidine by D162Q TK (K-m = 6.67 mu M) relative to wild-type enzyme (K-m = 0.56 mu M) was observed and the absence of any alteration in K-m for ATP suggests that D162 participates in nucleoside binding, Furthermore, the K-i for dTMP is significantly higher for D162Q TK than for HSV-1 TK which is indicative of a shared or overlapping binding site with thymidine, This assessment: is further supported by the different inhibition patterns of D162Q and wild-type TKs observed using [alpha-P-32]5-N(3)dUMP photoaffinity labelling in the presence of thymidine, ganciclovir or dTMP, interestingly, the K-i for dTTP was 30-fold lower for D1624 TK (K-i = 2.2 mu M) than for the wild-type enzyme (K-i = 65.8 mu M) which provides further evidence of the importance of D162 in TK function.